1. Introduction {#s0005}
===============

Regular physical activity (PA) is recommended for children and adolescents to promote health and well-being ([@b0340]), irrespective of disease status. However, PA plays a particularly potent role in youth with chronic conditions and is associated with slowing disease progression in conditions such as cerebral palsy (CP; [@b0160], [@b0310]). A common issue for children and adolescents with chronic conditions is the tendency to become less physically active with age and disease progression, which can lead to deconditioning and the initiation of a vicious negative spiral involving subsequent reductions in the ability to engage in PA ([@b0095], [@b0275]).

Careful consideration should be given when recommending PA to children and adolescents with some chronic conditions due to the enhanced nutritional, metabolic and energetic requirements associated with the condition or structural disability ([@b0335]). Children and adolescents with chronic conditions would, therefore, benefit from a greater understanding of the dose--response relationship between PA and health benefits in order to balance this with the potential negative sequalae that could ensue ([@b0235]). However, the current recommendation that children aged 5 to 18 years should accumulate, on average, at least 60 min of moderate-to-vigorous physical activity (MVPA) per day across the week ([@b0220]) has been developed for non-clinical populations and are therefore likely to have limited applicability to clinical populations. Indeed, a specific clinical guideline would warrant a higher degree of specificity and a cautious assessment of particular risks and benefits for each condition. It is therefore imperative to account for condition-specific factors that could be associated with exercise intolerance and/or an altered physiological response to exercise/PA ([@b0330]).

PA recommendations tailored for children and adolescents with clinical conditions, however, remain sparse ([@b0215]).

Objective methods used to assess PA, such as accelerometers, are appropriate for clinical settings due to the low participant burden and relatively low cost ([@b0280]). Accelerometers are capable of detecting patterns of PA accumulation, as well as information on PA frequency and intensity, such as sedentary time (SED), light physical activity (LPA) and MVPA ([@b0320]). Specifically, accelerometry measures velocity over a specific period of time, which can be translated into intensities of PA by using cut-points ([@b0320]). However, the generation of these cut-points is highly challenging, for example, even within one type of accelerometer, the MVPA cut-point in healthy youth varies from 400 to 3,600 counts^.^min^−1^ ([@b0060]). Whilst the accurate assessment of PA levels is particularly important in chronic conditions, inaccurate cut-points can result in over- or under-estimated predictions. Additionally, it is also important to consider the limitations associated with the use of accelerometry. For example, while accelerometry can accurately assess SED, it is not able to differentiate between various sedentary activities ([@b0155]). Moreover, factors such as brand and placement are likely to have an impact on the prediction of both SED and time spent in different PA intensities ([@b0140]).

Amongst the challenges of calibrating accelerometry are the different methods to translate (e.g., PA protocols and criterion method) and interpret (e.g., statistical approach) the accelerometer raw signals into biological and behavioural outcomes (e.g., cut-points). Indeed, a recent systematic review summarising different accelerometry calibration studies in healthy populations acknowledged the lack of cut-points that account for individual characteristics, such as demographic and physiological variations ([@b0075]). A key limitation of generalising cut-points developed for healthy populations to clinical populations is that they will not consider the altered resting metabolic rate (RMR) and higher energy expenditure (EE) for a given activity often evident in youth with chronic conditions ([@b0015], [@b0110], [@b0230]). Whilst some research has sought to calibrate accelerometry in paediatric clinical conditions ([@b0270], [@b0285]), the lack of standardisation, wide variability in protocol designs and lack of healthy matched controls limits interpretation ([@b0175]). Indeed, this systematic review can contribute by providing recommendations regarding the most appropriate criterion references, types of activities and statistical analyses to calibrate and cross-validate the cut-points.

The aim of this systematic review was to provide a critical overview of the protocols used to calibrate and validate accelerometry-derived MVPA cut-points in children and adolescents with clinical conditions and identify key parameters and considerations for future research.

2. Methods {#s0010}
==========

This review was performed in accordance with the Preferred Reporting items for Systematic Review and Meta-Analysis statement ([@b0170], [@b0210]) and is registered on the International Prospective Register of Systematic Review (PROSPERO registration ID: CRD42016053880).

2.1. Search methods {#s0015}
-------------------

The search was performed between March and July of 2017 using six databases (PubMed, SPORTDiscus, ScienceDirect, Scopus, ISI Web of Knowledge, Wiley Online Library). A Population Intervention Comparison Outcome (PICO) framework was adopted to build and structure the search; a detailed description of the search protocol is available on the [web-appendix](#s0100){ref-type="sec"}. The protocol and search strategy were reviewed by an experienced librarian and a pilot was performed to ensure the suitability of the criteria and search terms. The search terms were in accordance with the 2017 Medical Subject Headings and were inserted as keywords to all the databases and platforms. The search terms were: acceleromet\*; acceleromet\* AND (validation OR calibration); acceleromet\* AND physical activity; wearable monitors AND (calibration OR validation); physical activity AND (calibration OR validation); acceleromet\* cut-points; acceleromet\* cut-points; energy expenditure AND acceleromet\*; and classification AND physical activity intensities. The reference lists of relevant reviews and of all the studies included therein were examined for studies matching the inclusion criteria.

2.2. Eligibility criteria {#s0020}
-------------------------

Studies published in English from the year 2000 which generated MVPA accelerometry cut-points for accelerometry in children and adolescents (5 to 18 years) with any chronic clinical condition (disease of long duration and slow progression; [@b0145]) were included. Only studies published after the year 2000 were included in order to avoid inclusion of outdated accelerometers. Non-English, non-human and unpublished studies, book chapters, theses, monographs, dissertations and abstracts were not included. Studies in adults, or calibrating for healthy populations, sedentary behaviour or wheelchair users were excluded. Thus, studies using accelerometers along with additional technologies such as a microcontroller were not included.

2.3. Data extraction and management {#s0025}
-----------------------------------

An EndNote X7 (Clarivate Analytics, US) database was created with potential studies, and the lead author screened all the titles and abstracts. All full-texts selected by the first author (MSB) were screened by two co-authors (MAM and KAM) according to the pre-established inclusion criteria. [Supplementary information](#s0100){ref-type="sec"} for each study was consulted when available. In the case of missing information or variables required for completion of the extraction sheet, study authors were contacted, however, no additional data was provided. Data was extracted from the included full-texts by MSB and reviewed by KAM and MAM ([Table 1](#t0005){ref-type="table"}). Any discrepancies were discussed by the three authors until a consensus was reached.Table 1Summary of the data extracted from the included studies.Data extraction fieldInformation extracted*Context and participants*The author, year and sample size of the study; participant characteristics such as age, health status, height, weight, BMI, ethnicity; and covariates measured such as self-report questionnaire data and health scales related to disease assessments were extracted.*Study design and methods used*Any information related to the accelerometer, such as accelerometer model (e.g., number of axes); accelerometer placement (e.g., wrist \[dominant/non-dominant\], hip, chest); accelerometer settings (e.g., epoch, sampling frequency, use of low frequency filter); and data processing decisions (e.g., wear-time criteria) were extracted. Additionally, any information related to the calibration protocol, such as protocol design (e.g., laboratory-based, field-based, daily-life protocol); duration of the protocol; adjustment of specific variables (e.g., age, body mass); performance of individual calibration; criterion measure (e.g., energy expenditure, direct observation, heart rate); resting metabolic rate assessment; statistical approach (e.g., ROC-curve analyses, linear regression, machine learning); validation method (e.g., validation, cross-validation leave-one-out, cross-validation k-fold); and assessment for agreement (e.g., Kappa, Bland-Altman) were also extracted.*Findings*The extracted outcomes were protocol design and cut-points. All the extracted protocols were classified in four categories: laboratory-based (walking or running, over-ground or on a treadmill), free-living (assessment of participant routine), daily-life (daily-life activities performed at the research site), and mixed (at least two of laboratory-based, free-living and daily-life) protocols.*Quality of the study*checklist sheet.

The risk of bias was assessed independently by MSB and MAM using a specific checklist ([Table 2](#t0010){ref-type="table"}) created according to previous recommendations for calibration protocols ([@b0030], [@b0130], [@b0320]). This checklist considers six elements of the calibration protocol (sample characteristics, accelerometry settings, criterion measure, statistical approach for calibration, and statistical approach for validation) to rate studies as good, fair or poor according to the criteria described in [Table 2](#t0010){ref-type="table"}. The inter-rater reliability was calculated using Kappa scores with 0.8 as the minimum acceptable inter-rater agreement ([@b0195]). Where any discrepancies arose following the risk assessment, all three authors involved in the screening and data extraction (MSB, MAM and KAM) discussed these until a consensus was reached.Table 2Quality and risk assessment criteria according to descriptive variables and study design.StandardPoorFairGood1. Sample CharacteristicsStudy did not include any descriptive variables other than age and sex.Study included height, weight, body mass index and variables specific to the clinical condition.Study included height, weight, body mass index, ethnicity, resting metabolic rate, maturity stages and variables specific to the clinical condition.2. Accelerometry SettingsStudy described accelerometer model.Study included accelerometer model, number of axes and placement position.Study included accelerometer model, number of axes, placement, sampling frequency, epoch length and any filtering techniques.3. Protocol DesignCalibration protocol composed by walking or treadmill test.Calibration used a mixed protocol (daily-life activities and a treadmill test).Mixed protocol combining daily-life activities, laboratory protocol test on a treadmill and free-living assessments.4. CriterionSpeed or direct observation.Heart rate or metabolic equivalent.Energy expenditure (including resting metabolic rate estimation\*).5. Statistical Approach for CalibrationLinear regression or Individual linear regression.ROC curve analyses.Machine learning techniques, hierarchical models or multilevel modelling, adjusting for factors related to participants characteristics and to the pathophysiology of the clinical condition to develop the cut-point.6. Statistical Approach for ValidationNo validation assessment.Leave-one-out cross-validation and agreement assessment using Bland-Altman or kappa score.K-fold cross-validation using different samples and activities. Agreement assessment using Bland-Altman or Kapa score, and estimates the intraclass correlation coefficient, and/or limits of agreement.[^2]

A narrative synthesis of the studies was performed due to the heterogeneity of calibration protocols encountered, covering the topics of the protocol design, description of, and adjustment for, disease-specific factors, accelerometry model and settings, criterion measure and the statistical approach for generating and validating the cut-points. All cut-points in counts·min^−1^ were reintegrated to counts·15 s^−1^ epochs, which is commonly used in youth, to allow inter-study comparability.

3. Results {#s0030}
==========

A total of 543,741 titles were found across all databases, with 540,630 titles remaining following the removal of duplicates. Following initial screening, 619 articles were selected by the main author for full-text assessment. In total, 614 studies were subsequently excluded, primarily due to being in a healthy population (279 studies; [Fig. 1](#f0005){ref-type="fig"}). A list of all full-text studies that were excluded can be obtained from the correspondent author. Five studies ([@b0065], [@b0190], [@b0250], [@b0270], [@b0285]), including 347, 9--15 year old, participants, with a total of 24 generated MVPA cut-points for seven clinical conditions, were included in the final synthesis. The clinical conditions were: CP, intellectual disabilities, CF, congenital heart diseases (CHD), haemophilia (HE), inherited muscle disease (IMD), juvenile idiopathic arthritis (JIA; [Table 3](#t0015){ref-type="table"}).Fig. 1PRISMA flow chart presenting the systematic literature search.Table 3Summary of included studies calibrating accelerometry in paediatric clinical groups.StudiesParticipantsAccelerometerCalibration ProtocolStatistical ApproachOutcomeAuthor, yearSample size (n)\
Health status\
Control Group\
Sex (boy/girl)\
Age (range or mean ± SD)\
Height (mean ± SD)\
Weight (range or mean ± SD)\
BMI (range or mean ± SD)\
Ethnicity\
CovariatesDevice Model\
Number of axes\
Placement\
Sampling frequency\
Filter\
Epoch\
Sampling duration\
Wear timePhysiological/\
Observational\
EE estimation\
RMR estimation\
Individual calibration\
Protocol type\
DurationCalibration\
Validation\
AgreementCut-Points/\
Equation[@b0285]n = 51\
Cerebral Palsy\
GMFCS I (27)\
GMFCS II (12)\
GMFCS III (12)\
Control: 0\
28 girls\
12 ± 3 years\
147.0 ± 16.5 cm\
46.8 ± 19.0 kg\
GMFCSActiGraph GT3X\
Tri-axial\
Right hip\
30 Hz\
Epoch: 1 sPhysiological: VO~2~\
Resting VO~2~: Schofield\
Individual calibration: no\
Protocol type: Mixed -- daily-life and walking\
Duration: 120 minCalibration: Binary DT\
Validation: LOOCV\
Agreement: Kappa and ROCCut-points (counts·15 s^−1^)\
All levels:\
LPA: \< 72\
GMFCS I\
MVPA: 724\
GMFSC II\
MVPA: 685\
GMFCS III\
MVPA: 669[@b0250]n = 18\
Cerebral Palsy\
Control: no\
11.4 ± 3.2 years\
147.0 ± 18.5 cm\
44.6 ± 16.9 kg\
BMI: 20 ± 4.5 kg·m^−2^\
GMFCSRT3\
Right hip\
Epoch: 60 sPhysiological: VO~2~\
RMR: Oxford equation\
Individual calibration: none\
Protocol type: laboratory\
Duration: 36 minCalibration:\
ROC curve\
Validation: none\
Agreement: Kappa scoreCut-points (counts·min^−1^):\
LPA: 52\
MVPA: 689.3[@b0065]n = 29\
Cerebral palsy\
Control: no\
13 girls\
12.5 ± 2.0 years\
156.6 ± 11.0 cm\
47.7 ± 16.1 kg\
GMFCSActiGraph (7164)\
Uniaxial\
Least affected hip\
10 Hz\
Epoch: 1 sPhysiological: VO~2~\
RMR: Schofield equation\
Individual calibration: none\
Protocol type: laboratory\
Duration: 60 minCalibration:\
ROC curve\
Validation: none\
Agreement: noneCut-points (counts·min^−1^):\
LPA: 1627.3\
MVPA: 2942.1\
VIG: 4683.6[@b0190]n = 50\
Validation: 36\
Intellectual disabilities\
Control: no\
37 girls\
9.54 ± 1.09 years\
143 ± 0.9 cm\
39.33 ± 10.28 kg\
BMI: 19.9 ± 3.8 kg·m^−2^ActiGraph Wgt3X+\
Tri-axial\
Right hip\
30 Hz\
Epoch: 10 sPhysiological: Direct Observation\
Individual calibration: none\
Protocol type: Daily-life\
Duration: 45 minCalibration: ROC\
Validation: LOOCV\
Agreement: Kappa scoreCut-points (counts·min^−1^):\
VA:\
SED: 507\
MPA: 1008--2300\
VPA: 2301\
MVPA: 1008\
VM:\
SED: 1863\
MPA: 2610--4214\
VPA: 4215\
MVPA: 2610[@b0270]n = 195\
Control: n = 29\
13 girls\
13.1 ± 2.8 years\
162 ± 16 cm\
57.6 ± 20 kg\
Skinfold: 38 ± 17\
Tanner stages: 30% (stages 1--2), 70% (stage 3)\
CHAQ: 0.15 ± 0,26\
PedsQL: 83 ± 9\
Cystic fibrosis (n = 32)\
14 girls\
12.8 ± 2.9 years\
156 ± 16 cm\
45 ± 14 kg\
Skinfold: 31 ± 13\
Tanner stage: 19% (stages 1--2), 81% (stage 3)\
CHAQ: 0.27 ± 0.3\
PedsQL: 78 ± 12\
Congenital heart disease (n = 15)\
5 girls\
13.6 ± 3.3 years\
161 ± 17 cm\
54 ± 17 kg\
Skinfold: 42 ± 15.5\
Tanner Stage: 38% (stages 1--2), 62% (stage 3)\
CHAQ: 0.17 ± 0.3\
PedsQL: 72 ± 12\
Haemophilia (n = 28)\
0 girls\
12.4 ± 3.3 years\
156 ± 19 cm\
53 ± 20.7 kg\
Skinfold: 40 ± 20\
Tanner Stage: 27% (stages 1--2), 73% (stage 3)\
CHAQ: 0.25 ± 0.4\
PedsQL: 82 ± 16\
Idiopathic muscular dystrophies (n = 30)\
8 girls\
12 ± 3.4 years\
146 ± 22 cm\
41 ± 14 kg\
Skinfold: 41 ± 18\
Tanner stage: 70% (stages 1--2) 30% (stage 3)\
CHAQ: 0.8 ± 0.7\
PedsQL: 68 ± 17\
Juvenile dermatomyositis (n = 31)\
20 girls\
13.4 ± 2.3 years\
159 ± 11 cm\
52 ± 14 kg\
Skinfold: 48 ± 17\
Tanner stage: 27% (stages 1--2), 73% (stage 3)\
CHAQ: 0.4 ± 0.6\
PedsQL: 77 ± 15\
Juvenile arthritis (n = 31)\
23 girls\
12.7 ± 2.6 years\
154 ± 12 cm\
47 ± 14 kg\
Skinfold: 46 ± 22\
Tanner stage: 32 (stages 1--2), 68% (stage 3)\
CHAQ: 0.5 ± 0.5\
PedQL: 72 ± 13ActiGraph (7164) and Actical\
Uniaxial\
Right hip\
10 HZ / 32 Hz\
Epoch: 15 sPhysiological: VO~2~ and HR\
RMR: 2 h fasting -- 20 min in rest\
Individual calibration: no\
Protocol type: Mixed: laboratory and daily-life\
Duration: 240 minCalibration: Mixed regression models for equation, ROC curve for cut-points.\
Validation: LOOCV\
Agreement: noneChronic disease (combined) -- ActiGraph\
SED: 10\
LPA: 10--426\
MVPA: 426--785\
Chronic disease (combined) -- Actical\
SED: 10\
LPA: 17--288\
MVPA: 289--570\
Cystic fibrosis - ActiGraph\
SED: 10\
LPA: 10--487\
MVPA: 487--852\
Cystic fibrosis - Actical\
SED: 5\
LPA: 5--368\
MVPA: 368--1025\
Congenital heart disease - ActiGraph\
SED: 10\
LPA: 10--349\
MVPA: 349--785\
Congenital heart disease - Actical\
SED: 9\
LPA: 9--349\
MVPA: 349--633\
Haemophilia - ActiGraph\
SED: 17\
LPA: 17--432\
MVPA: 432--788\
Haemophilia - Actical\
SED: 19\
LPA: 19--306\
MVPA: 306--1114\
Inherited muscle disease - ActiGraph\
SED: 37\
LPA: 37--663\
MVPA: 663--972\
Inherited muscle disease - Actical\
SED: 14\
LPA: 14--297\
MVPA: 297--523\
Juvenile dermatomyositis- ActiGraph\
SED: 14\
LPA: 14--172\
MVPA: 172--543\
Juvenile dermatomyositis - Actical\
SED: 18\
LPA: 10--166\
MVPA: 166--601\
Juvenile arthritis - ActiGraph\
SED: 25\
LPA: 25--255\
MVPA: 255--771\
Juvenile arthritis - Actical\
SED: 19\
LPA: 19--152\
MVPA: 152--542[^3]

The inter-rater Kappa score for risk of bias was 0.80, with authors disagreeing regarding 'accelerometry settings', and were resolved after MSB and MAM discussed each point, resulting in a Kappa score of 1. Most studies (n = 4) were classified as fair for sample characteristics, with only one study scoring as good. One study scored as fair, and four as good, for accelerometry settings, with three and two studies classified as fair and good, respectively, for protocol design. For criterion measure, one scored as good, three as fair and one as poor. The majority (n = 4) of the studies scored as fair for statistical approach for calibration, with only one scoring as good. Finally, regarding the statistical approach for validation, three studies scored as fair and two as poor ([Table 4](#t0020){ref-type="table"}).Table 4Checklist Risk of Bias Assessment Results.StudySample CharacteristicsAccelerometry SettingsProtocol DesignCriterionStatistical Approach for CalibrationsStatistical Approach for Validations[@b0065]FairFairPoorFairFairPoor[@b0250]FairGoodFairPoorFairFair[@b0285]FairGoodFairFairGoodFair[@b0190]FairGoodPoorFairFairPoor[@b0270]GoodGoodFairGoodFairFair

Quality of life ([@b0300]), maturity status ([@b0105], [@b0270]) and a generic health questionnaire ([@b0120], [@b0150]) were used as co-variates. Additionally, three studies ([@b0065], [@b0250], [@b0285]) used the specific classification system for CP (Gross Motor Function Classification System - GMFCS). Whilst covariates were considered by most of the included studies, only one study ([@b0270]) adjusted for disease-specific factors when generating the cut-points, although no formal description was provided on the variables included in the model. None of the studies investigated whether the disease-specific factors and participant demographics impacted on the developed cut-points.

3.1. Accelerometers {#s0035}
-------------------

Sixteen of the included MVPA cut-points were developed for different ActiGraph models ([@b0190], [@b0250], [@b0270], [@b0285]), seven for Actical ([@b0270]) and one for Tritrac-R3D (RT3; [Table 5](#t0025){ref-type="table"}; ([@b0250]). This translates to 15 MVPA cut-points derived from the vertical axis (VA) ([@b0065], [@b0270]) and nine from the vector magnitude (VM; ([@b0190], [@b0250], [@b0285]). Three studies utilised hip-worn accelerometry on the right side ([@b0190], [@b0270], [@b0285]) and two studies calibrating for CP placed the accelerometer on the least affected side ([@b0065], [@b0250]). The sample frequency varied between 1 and 32 Hz, with one study ([@b0065]) not specifying this information. Two studies used an epoch of 15 s ([@b0270], [@b0285]), with others using 1 s ([@b0065]), 10 s ([@b0190]) and 60 s ([@b0250]).Table 5Summary of the accelerometer models used by the included studies.Name / ModelManufacturerWeight and SizeMemory CapacityAxisFrequency SamplingActiGraph 7164 (CSA)ActiGraph LLC Pensacola, FL45.5 g\
5.1 × 4.1 × 1.5 cm22 days of data with 60 s epochUniaxial10 HzActiGraph GT3XActiGraph LLC Pensacola, FL27 g\
3.8 × 3.7 × 1.8 cm378 days using 60 s epochTri-axial30 HzActiGraph wGT3X+ActiGraph LLC Pensacola, FL19 g\
4.6 × 3.3 1.5 cm38 days 100 HzTri-axial30--100 HzActicalMini-Mitter Sunriver, OR17.5 g\
2.8 × 2.7 × 1.0 cm45d using 60 s epochUniaxial32 HzResearch Tracker accelerometer (RT3)StayHealthy, Inc; Monrovia, California71.5 g\
71 × 56 × 28 mm30 daysTri-axial0.017--1 Hz

3.2. Calibration protocol settings {#s0040}
----------------------------------

A daily-life calibration protocol was the most commonly used (n = 3), generating 22 MVPA cut-points, with only two studies utilising a laboratory-based protocol ([@b0065], [@b0250]). Indirect calorimetry was the most common physiological criterion used for calibration ([@b0065], [@b0250], [@b0270], [@b0285]), with one study using direct observation ([@b0190]). The protocol duration varied from 35 to 240 min. Resting metabolic rate was estimated by [@b0270] using the Weir equation, whereas [@b0065], [@b0285] used the Schofield equation and [@b0250] the Oxford equation. As [@b0190] developed cut-points through direct observation, a RMR estimation was not required. All included studies performed a group calibration rather than individual calibrations.

3.3. Statistical approach {#s0045}
-------------------------

Fourteen MVPA cut-points were developed through mixed regression models ([@b0270]), six using machine learning (regressing trees; [@b0285]), and four through Receiver Operating Characteristic (ROC) analysis ([@b0065], [@b0190], [@b0250], [@b0270]). Only one study did not perform any kind of validation ([@b0065]), with all other validations performed using leave-one-out cross-validations. No studies utilised independent samples or a different set of activities to cross-validate. Eighteen ([@b0065], [@b0250], [@b0270], [@b0285]) of the generated cut-points were validated through comparison of previously established cut-points developed for healthy populations ([@b0115], [@b0225], [@b0240], [@b0295]). Three studies ([@b0190], [@b0250], [@b0285]) utilised the Kappa score for agreement assessment, whereas two studies ([@b0065], [@b0270]) performed ANOVA.

3.4. Outcome {#s0050}
------------

The disease-specific MVPA cut-points ranged from 152 to 735 counts·15 s^−1^, with 19 MVPA cut-points presented in counts·15 s^−1^, and four presented in counts·min^−1^ ([Table 6](#t0030){ref-type="table"}). The sensitivity of the cut-points ranged from 37 to 91%, and the specificity ranged from 85 to 97%. Cerebral palsy was the mostly widely studied clinical condition, with eight cut-points developed across three studies ([@b0065], [@b0250], [@b0285]). [@b0285] generated cut-points for different degrees of CP severity, with fair to excellent accuracy, demonstrating better accuracy (lower rates of misclassification, particularly for GMFCS III and for LPA classification) than [@b0115] cut-points. In contrast, [@b0250], [@b0065] did not develop specific cut-points for different GMFCS levels or perform a leave-one-out cross validation, using specificity and sensitivity as a measure of validation. [@b0065] cut-points showed no significant improvement in PA classification accuracy compared to healthy population cut-points, whilst the MVPA cut-points of [@b0250] demonstrated moderate classification agreement ([@b0115], [@b0240], [@b0295]). Similarly, [@b0270] also applied healthy population cut-points ([@b0115]) to their participants with various chronic conditions (CF, IMD, JIA, HE and CHD), which resulted in poor-to-moderate sensitivity in PA classification. Most of the disease-specific cut-points developed were below the previously established MVPA cut-points for healthy populations (e.g., 2,020 to 8,199 counts·min^−1^).Table 6Summary and validity of the clinical-specific moderate-to-vigorous cut-points.Conditions (n)StudyReason for splitCut-points MVPA (original)Cut-points MVPA converted to counts·15 s^−1^Criterion ValidityCerebral palsy **(7)**[@b0285]GMFCS I / VA535 (counts·15 s^−1^)N/ALOOCV -- 81.1%[@b0285]GMFCS II / VA333 (counts·15 s^−1^)N/ALOOCV -- 76.7%[@b0285]GMFCS III/VA200 (counts·15 s^−1^)N/ALOOCV -- 82.9%[@b0285]GMFCS I / VM724 (counts·15 s^−1^)N/ALOOCV -- 80.5%[@b0285]GMFCS II / VM685 (counts·15 s^−1^)N/ALOOCV -- 75.6%[@b0285]GMFCS III / VM669 (counts·15 s^−1^)N/ALOOCV -- 84.2%[@b0250]N/A689.3 (counts·min^−1^)172.3Se -- 86.7% / Sp -- 91.9%[@b0065]N/A2942 (counts·min^−1^)735.5Se -- 91.4% / Sp -- 86.2%Intellectual disability **(2)**[@b0190]VA1008 (counts·min^−1^)252LOOCV -- 93%\
Se -- 91% / Sp -- 95%[@b0190]VM2610 (counts·min^−1^)652LOOCV -- 87%\
Se -- 91% / 84%Cystic fibrosis **(2)**[@b0270]CF / ActiGraph 7164487 (counts·15 s^−1^)N/ASe -- 71% / Sp -- 85%[@b0270]CF / Actical 7164368 (counts·15 s^−1^)N/ASe -- 51% / Sp -- 91%Chronic heart disease **(2)**[@b0270]CHD / ActiGraph 7164349 (counts·15 s^−1^)N/ASe -- 42% / Sp -- 85%[@b0270]CHD / Actical349 (counts·15 s^−1^)N/ASe -- 41 / Sp -- 94%Inherited muscle disease **(2)**[@b0270]IMD / ActiGraph 7164663 (counts·15 s^−1^)N/ASe -- 81% / Sp -- 90%[@b0270]IMD / Actical297 (counts·15 s^−1^)N/ASe -- 47% / Sp -- 96%Juvenile dermatomyositis **(2)**[@b0270]JDM /ActiGraph 7164172 (counts·15 s^−1^)N/ASe -- 41% / Sp -- 90%[@b0270]JDM / Actical166 (counts·15 s^−1^)N/ASe -- 37% / Sp -- 94%Haemophilia (2)[@b0270]HE / Actical306 (counts·15 s^−1^)N/ASe -- 49% / Sp -- 92%[@b0270]HE / ActiGraph 7164432 (counts·15 s^−1^)N/ASe -- 53% / Sp -- 92%Juvenile arthritis **(2)**[@b0270]JIA / Actical152 (counts·15 s^−1^)N/ASe -- 49% / Sp -- 94%[@b0270]JIA / ActiGraph 7164255 (counts·15 s^−1^)N/ASe -- 41% / Sp -- 90%Overall (CF, JA, HE, CHD, JDM, IMD) **(2)**[@b0270]Overall Diseases / Actical289 (counts·15 s^−1^)N/ASe -- 77% / Se -- 97%[@b0270]Overall Diseases / ActiGraph 7164426 (counts·15 s^−1^)N/ASe -- 78% / Sp -- 94%[^4]

4. Discussion {#s0055}
=============

Twenty-four MVPA cut-points were extracted from five studies across seven different paediatric clinical groups. Overall, the review revealed little consensus with regards to MVPA cut-points, due to, at least in part, the relatively low number of calibration studies and broad range of protocol designs and accelerometer settings used in the studies, thereby limiting inter-study comparisons. Nonetheless, despite this, a thorough methodological quality assessment of the included studies was performed, which contributed to a higher transparency and aided the interpretation of the outcomes. Moreover, this review presented a critical analysis of the methodological challenges faced when developing cut-points for clinical paediatric populations, providing recommendations for future studies.

4.1. Calibration protocol for paediatric clinical populations {#s0060}
-------------------------------------------------------------

The majority of the included studies utilised daily-life ([@b0190]) or mixed ([@b0270], [@b0285]) protocols composed of daily-life and laboratory protocols. To accommodate different disease and disability levels, [@b0270] adjusted their laboratory-based protocol by performing two different treadmill tests based on 6-min walking test performance. Whilst the protocol can greatly impact the PA classification, the physiological criterion adopted is equally important. For example, both [@b0285], [@b0270] utilised indirect calorimetry as criterion, which therefore considers the higher energetic demand associated with a given activity in some chronic conditions ([@b0315]). Specifically, diseases associated with chronic inflammation (e.g., CF, obesity) and musculoskeletal adaptations (e.g., CP, JIA, IMD) can reduce exercise tolerance, leading to chronic deconditioning and a higher EE demand for a given activity ([@b0205]).

It is well known that the majority of paediatric clinical conditions are associated with altered cardiometabolic demands ([@b0025]). Thus, studies calibrating accelerometry for these populations should adopt EE as their criterion method. Another important consideration is that RMR changes dramatically according to maturity, disease and health parameters ([@b0185]), such as chronic inflammation and reductions in PA ([@b0055], [@b0100]). Specifically, individuals with CF often have a greater RMR, which can be explained to some extent by pulmonary impairment ([@b0090]) and increased cost of breathing ([@b0040], [@b0125]). Conversely, children with certain types of CP have a reduced RMR due to a lower energetic requirement at rest and altered body composition (e.g., reduced fat free mass and lean body mass; [@b0020], [@b0015], [@b0255]). Consequently, condition-specific calibration protocols adopting EE as the criterion should measure RMR. Despite using indirect calorimetry in their protocols, some of the included studies utilised Schofield and Oxford equations ([@b0065]) to determine RMR. Whilst such equations may provide a low-cost estimation of RMR, they are based on chronological, rather than biological, age ([@b0200]), and do not account for sex or health status. This may lead to an inaccurate estimation of RMR, and consequently of EE, in clinical populations ([@b0080], [@b0135]). Therefore, the measurement of oxygen uptake at rest should be utilised to provide a precise estimation of RMR, and consequently enhance the accuracy of the disease-specific cut-points in youth with chronic conditions ([@b0270]).

It is also important to consider the influence of disease severity within a condition, which is likely to affect the relative energetic demand, as might differences in the treatment and medication strategies between patients ([@b0315]). Indeed, [@b0250], [@b0065] did not stratify their sample by the GMFCS scale, resulting in large heterogeneity of CP-severity across participants, with some children not able to finish the protocol. In contrast, [@b0285] demonstrated that the relationship between EE and activity counts changed significantly according to GMFCS level, with children classified as level III having greater EE during locomotion when compared to levels I and II.

4.2. Statistical approach {#s0065}
-------------------------

The statistical approach chosen is highly influential in the translation of the physiological criterion into cut-points. Linear regression, which was initially one of the most commonly used methods for calibration, cannot account for the non-linear relationship between PA and EE ([@b0130], [@b0320]). Consequently, most of the studies included in this review utilised ROC analyses to develop their cut-points. Whilst ROC is more accurate than linear regression ([@b0320]), it is dependent on the number of participants and does not allow adjustment of disease-specific factors ([@b0260]).

Alternatively, mixed regression modelling is an exploratory analysis, particularly useful due to its flexible nature that allows the inclusion of disease-specific factors ([@b0320]). [@b0270] utilised mixed regression modelling to control for disease-specific factors to generate predictive equations for children and adolescents with CF, HE, JIA, CHD and IMD ([@b0005], [@b0180]), reporting that heart rate improved the model and lowered the standard error associated with the prediction. These findings agree with those in healthy populations ([@b0010]), with the improvements in standard error likely to be attributable to the reduction of the inter-individual variability caused by the adjustment of physiological signals. It is noteworthy that whilst a certain degree of accuracy can be achieved with cut-points, recent PA research has moved towards using machine learning. Indeed, more complex machine learning analysis have provided a higher degree of accuracy in comparison with traditional cut-points ([@b0050], [@b0265], [@b0260], [@b0320]). Despite this, a calibration protocol is still required even when using those techniques. Indeed, machine learning can also be used to develop cut-points, for example, [@b0285] used Binary Decision Trees to generate CP-specific cut-points. Whilst machine learning provides high accuracy, evidence suggests that considerable bias can arise from using a small sample size ([@b0070]). Alternatively, approaches such as using different testing and training data sets, and testing algorithm performance (i.e., nested cross-validation), can provide unbiased performance estimates even with small sample sizes ([@b0290]).

A cross-validation analysis of the cut-points evaluates the predictive models to ensure validity and avoid over-fitting, and it can be performed through different methods such as the k-fold or leave-one-out cross-validation. Specifically, considering that the developed cut-points might be biased to the sample characteristics or to the calibration protocol design, the use of an independent sample with a different set of activities for cross-validating the cut-points is recommended ([@b0320]). [@b0270], [@b0285] applied a leave-one-out cross-validation, identified as the most appropriate approach when working with smaller samples ([@b0325]), or to lessen the burden on the participants. It is further recommended that the disease-specific cut-points should also be validated against a healthy matched control group to ensure that potential cut-point discrepancies are a result of the pathophysiology rather than from the protocol design. Further to the cross-validation, agreement measures, such as Kappa score and Bland-Altman, indicate whether two methods can be used concomitantly or interchangeably, thereby facilitating inter-study comparisons ([@b0045]). Alternatively, recent research has used a statistical equivalence test to measure agreement, which has been shown to be more appropriate for highlighting similarities between methods ([@b0085], [@b0165]). Particularly, the performance of agreement measures between activity counts and the criterion measures in a calibration protocol ensures that both measurements are comparable, avoiding further errors to the developed cut-points ([@b0320]).

4.3. Outcome: cut-points {#s0070}
------------------------

Cross-validation identified moderate to excellent accuracy for most of the disease-specific cut-points. Considerable inter-study discrepancies were found when comparisons were made between the disease-specific and previously established healthy population cut-points. For example, whilst [@b0285] found that applying cut-points developed for healthy populations ([@b0115]) to CP children resulted in poor accuracy and misclassification, [@b0250], [@b0065] demonstrated fair to moderate accuracy ([@b0240], [@b0295]). Indeed, converse to [@b0250], [@b0065], [@b0285] calibrated for each level of the GMFCS instead of performing an overall calibration, and applied machine learning techniques to generate the CP cut-points, presenting higher specificity than the cut-points developed for healthy populations. Furthermore, [@b0270] also found that their disease-specific cut-points (CF, CHD, HE, JIA and IMD) had improved accuracy when compared with standard cut-points, thereby supporting the notion that specific cut-points are necessary for clinical populations.

Given that SED is mainly classified based on stationary activities and therefore does not consider musculoskeletal disabilities, it is unsurprising that some studies ([@b0065], [@b0250], [@b0285]) demonstrated fair to excellent accuracy when utilising healthy population-based SED cut-points for children with less severe CP. Despite this, poor classification of LPA may affect specific clinical populations, such as CP ([@b0305]), who may not be able to engage in MVPA activities, and would therefore greatly benefit from a reduction in SED ([@b0245]). Specifically, considering that daily PA is a composite measure, an increase in LPA could be associated with a reduction in SED and enhancement on the total volume of PA ([@b0035]). Indeed, estimation of LPA for children with CP through standard cut-points, such as [@b0115], [@b0295], presented poor to fair classification accuracy ([@b0065], [@b0250], [@b0285]). Additionally, the lack of standardisation regarding protocol design and statistical approach hinders the applicability of the cut-points, which might explain the variability found between cut-points developed for the same clinical condition. Consequently, age- and sex-matched healthy control groups are essential to elucidate whether the differences observed in the disease-specific protocol are due to the disease severity or to protocol discrepancies. However, only one study ([@b0270]) included a control group although this was only used for baseline comparisons.

4.4. Strengths and limitations {#s0075}
------------------------------

The present systematic review is associated with numerous strengths. Firstly, an experienced librarian was consulted to revise the initial protocol and a pilot search was conducted to minimise errors, leading to changes in the eligibility of participants, outcomes, risk of bias assessment and analysis. Moreover, the initial search terms were adapted following advice from the librarian. The pilot search generated a large number of studies for participants across the lifespan and health continuum, therefore, the inclusion criteria for participants were limited to only children and adolescents with clinical conditions. Nevertheless, the literature was initially screened to capture all calibration studies for healthy and clinical populations. Whilst this strategy resulted in an extensive search, it also minimised the possibility of missing studies calibrating for a clinical condition. However, this strategy is not without limitations, as it required having only one author screen all the titles and abstracts. Nonetheless, different approaches were adopted to minimise error. Specifically, an EndNote library was created, and the same search strategy was used for all databases. Whilst double data entry was not performed, a data extraction sheet was created and checked by two co-authors (KAM, MAM), and subsequently made available to all authors during the extraction process.

A qualitative data synthesis was performed due the heterogeneity of calibration protocols and the calculation of cut-point effect sizes not being possible, thereby precluding a meta-analysis from being performed. The heterogeneity of the protocols can partially be explained by the inclusion of a broad range of clinical conditions. However, whilst the comparison of numerous clinical conditions of a different nature may be questioned, the primary aim of the review was to investigate the structure of different calibration protocols and how they accounted for the pathophysiology of the respective conditions. Despite the varying nature of the conditions included, only a small range of studies calibrated accelerometry in clinical populations, which hinders further conclusions regarding the optimal protocol.

5. Conclusion {#s0080}
=============

Overall, this systematic review highlights the broad range of protocol designs and accelerometer settings of studies developing MVPA cut-points for children and adolescents with clinical conditions. Research seeking to develop disease-specific paediatric cut-points should consider the pathophysiology of the disease and seek to include a measure of EE, an accurately assessed RMR and a healthy comparison group. Moreover, all cut-points developed should be cross-validated. In summary, studies calibrating accelerometry in paediatric clinical populations are urgently required to establish an optimal calibration protocol. Subsequently, the enhancement in the assessment and surveillance of PA for clinical populations could lead to the development of more informed clinically specific PA guidelines.
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[^1]: on behalf of ActiveYouth SRC group.

[^2]: ROC: receiver operating characteristic. \*The criteria for a valid resting metabolic rate estimation was a minimum of 15 min of steady state, preferably adopting the formula of [@bib341].

[^3]: SD: standard deviation; BMI: body mass index; EE: energy expenditure; RMR: resting metabolic rate; GMFCS: gross motor function classification system; VO2: oxygen uptake, LOOV: leave-one-out cross-validation; ROC: receiver operating characteristic; SED: sedentary time; LPA: light physical activity; MVPA: moderate-to-vigorous physical activity; VIG: vigorous activity; CHAQ: childhood health assessment questionnaire; PedsQL: pediatric quality of life inventory.

[^4]: MVPA: moderate-to-vigorous physical activity; GMFCS: gross motor function classification system; VA: vector axial, VM: vector magnitude; LOOCV: leave-one-out cross-validation; Se: sensitivity; Sp: specificity; CF: cystic fibrosis; CHD: congenital heart disease; IMD: inherited muscle disease; JMD: juvenile dermatomyositis; HE: haemophilia; JA: juvenile arthritis.
